{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T19:06:03Z","timestamp":1793646363517,"version":"4.5.1"},"reference-count":45,"publisher":"Cambridge University Press (CUP)","issue":"5","license":[{"start":{"date-parts":[[2013,9,30]],"date-time":"2013-09-30T00:00:00Z","timestamp":1380499200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Nutr"],"published-print":{"date-parts":[[2014,3,14]]},"abstract":"<jats:p>Resveratrol (Res), a polyphenol that is abundant in many medicinal plants and is a selective oestrogen receptor modulator, exhibits multiple biological activities. In the present study, we determined whether Res prevents oestrogen deficiency-induced osteopenia and whether Res administration decreases pathological changes in the endometrium and lumen of the uterus compared with oestradiol replacement therapy (ERT). A total of sixty 3\u20134-month-old female Wistar rats were randomly divided into a sham-operated group (Sham) and five ovariectomy (OVX) subgroups, i.e. OVX rats as a control group (OVX); OVX rats receiving oestradiol valerate (ERT, 0\u00b78\u00a0mg\/kg); and OVX rats receiving Res 20, 40 and 80\u00a0mg\/kg. Daily oral administration was initiated at week 2 after OVX for 12 weeks. A dose\u2013response difference was observed in the effects of Res on bone mineral density (BMD) and trabecular microarchitecture. Only at the highest dose, bone loss was almost equivalent to that observed in the ERT group. The dose\u2013response effects of Res on the biochemical parameters (alkaline phosphatase, IL-6, TNF-\u03b1 and transforming growth factor-\u03b21 concentrations in the serum as well as urinary Ca and P excretion) and the expressions of receptor activator of nuclear factor \u03baB ligand (RANKL) and the RANKL:osteoprotegerin protein ratio in the femur were also observed. Furthermore, the thickening of the endometrium and the infiltration of lymphocytes were prevented in all the three Res-treated groups compared with the ERT group. In conclusion, Res treatment not only improves BMD and trabecular microarchitecture but also does not affect the uterus and Res might be a potential remedy for the treatment of postmenopausal osteoporosis.<\/jats:p>","DOI":"10.1017\/s0007114513003115","type":"journal-article","created":{"date-parts":[[2013,9,30]],"date-time":"2013-09-30T05:58:44Z","timestamp":1380520724000},"page":"836-846","source":"Crossref","is-referenced-by-count":60,"title":["Long-term resveratrol treatment prevents ovariectomy-induced osteopenia in rats without hyperplastic effects on the uterus"],"prefix":"10.1017","volume":"111","author":[{"given":"Haifeng","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuemin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiantian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziwei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huihui","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2013,9,30]]},"reference":[{"key":"S0007114513003115_ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2009.03.057"},{"key":"S0007114513003115_ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2009.05.017"},{"key":"S0007114513003115_ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2010.09.021"},{"key":"S0007114513003115_ref40","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2006.08.133"},{"key":"S0007114513003115_ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2009.02.014"},{"key":"S0007114513003115_ref2","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.2001.16.9.1665"},{"key":"S0007114513003115_ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2009.09.021"},{"key":"S0007114513003115_ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2011.09.030"},{"key":"S0007114513003115_ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2007.01.008"},{"key":"S0007114513003115_ref23","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M702452200"},{"key":"S0007114513003115_ref28","first-page":"27","article-title":"Noninfectious complications due to vascular access ports (VAPs) in Yucatan minipigs (Sus scrofa domestica)","volume":"45","author":"Ege","year":"2006","journal-title":"J Am Assoc Lab Anim Sci"},{"key":"S0007114513003115_ref25","doi-asserted-by":"publisher","DOI":"10.1055\/s-2008-1074550"},{"key":"S0007114513003115_ref45","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.b12-00445"},{"key":"S0007114513003115_ref44","doi-asserted-by":"publisher","DOI":"10.1111\/j.1834-7819.2012.01701.x"},{"key":"S0007114513003115_ref13","doi-asserted-by":"publisher","DOI":"10.1002\/mnfr.200400098"},{"key":"S0007114513003115_ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jnutbio.2007.09.004"},{"key":"S0007114513003115_ref22","doi-asserted-by":"publisher","DOI":"10.3177\/jnsv.46.78"},{"key":"S0007114513003115_ref38","doi-asserted-by":"publisher","DOI":"10.1139\/Y08-097"},{"key":"S0007114513003115_ref42","doi-asserted-by":"publisher","DOI":"10.1016\/j.regpep.2008.02.004"},{"key":"S0007114513003115_ref27","unstructured":"Food and Drug Administration (2002) Guidance for Industry and Review: Estimating the Safe Starting Dose in Clinical Trials for Therapeutics in Adult Healthy Volunteers. US Food and Drug Administration. http:\/\/www.fda.gov\/cder\/guidance\/index.htm."},{"key":"S0007114513003115_ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2007.04.003"},{"key":"S0007114513003115_ref20","first-page":"35","article-title":"[Comparative evaluation of the osteoprotective effects of resveratrol and resveratrol\/enalapril combination in the treatment of experimental osteoporosis]","volume":"75","author":"Faitel'son","year":"2012","journal-title":"Eksp Klin Farmakol"},{"key":"S0007114513003115_ref34","doi-asserted-by":"publisher","DOI":"10.1002\/jsfa.3972"},{"key":"S0007114513003115_ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2005.09.051"},{"key":"S0007114513003115_ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2010.02.006"},{"key":"S0007114513003115_ref21","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.460"},{"key":"S0007114513003115_ref43","doi-asserted-by":"publisher","DOI":"10.1159\/000341216"},{"key":"S0007114513003115_ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2004.02.007"},{"key":"S0007114513003115_ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.freeradbiomed.2009.03.011"},{"key":"S0007114513003115_ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.mod.2004.11.006"},{"key":"S0007114513003115_ref7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.24.8799"},{"key":"S0007114513003115_ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s001980170152"},{"key":"S0007114513003115_ref12","doi-asserted-by":"publisher","DOI":"10.1002\/mnfr.200500022"},{"key":"S0007114513003115_ref37","doi-asserted-by":"publisher","DOI":"10.1007\/s10038-008-0295-x"},{"key":"S0007114513003115_ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.acra.2008.05.019"},{"key":"S0007114513003115_ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2009.11.002"},{"key":"S0007114513003115_ref31","doi-asserted-by":"publisher","DOI":"10.3892\/ijmm.2013.1269"},{"key":"S0007114513003115_ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2010.09.053"},{"key":"S0007114513003115_ref36","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1365.035"},{"key":"S0007114513003115_ref41","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2008.12.005"},{"key":"S0007114513003115_ref24","doi-asserted-by":"publisher","DOI":"10.1089\/jmf.2005.8.14"},{"key":"S0007114513003115_ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2005.12.013"},{"key":"S0007114513003115_ref6","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djq527"},{"key":"S0007114513003115_ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2008.06.001"},{"key":"S0007114513003115_ref26","first-page":"1069","article-title":"Dose conversion among different animals and healthy volunteers in pharmacological study","volume":"9","author":"Huang","year":"2004","journal-title":"Chin J Clin Pharmacol Ther"}],"container-title":["British Journal of Nutrition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0007114513003115","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,22]],"date-time":"2019-04-22T18:37:34Z","timestamp":1555958254000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0007114513003115\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,30]]},"references-count":45,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,3,14]]}},"alternative-id":["S0007114513003115"],"URL":"https:\/\/doi.org\/10.1017\/s0007114513003115","relation":{},"ISSN":["0007-1145","1475-2662"],"issn-type":[{"value":"0007-1145","type":"print"},{"value":"1475-2662","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9,30]]}}}